|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CH03
|
|
gptkbp:CASNumber
|
609799-22-6
|
|
gptkbp:developedBy
|
gptkb:Vanda_Pharmaceuticals
|
|
gptkbp:hasMolecularFormula
|
C19H19NO2
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(C=C1)C(=O)N2CCC(CC2)OC3=CC=CC=C3)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tasimelteon
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
Hetlioz
|
|
gptkbp:mechanismOfAction
|
melatonin receptor agonist
|
|
gptkbp:molecularWeight
|
293.36 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
DB09078
11522621
9691457
CHEMBL2105751
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
elevated liver enzymes
nightmares
|
|
gptkbp:target
|
gptkb:MT1_receptor
gptkb:MT2_receptor
|
|
gptkbp:UNII
|
YFQ6T2UWK2
|
|
gptkbp:usedFor
|
treatment of insomnia
treatment of non-24-hour sleep-wake disorder
|
|
gptkbp:bfsParent
|
gptkb:MT2_receptor
gptkb:Non-24-hour_sleep-wake_disorder
gptkb:melatonin_receptors
|
|
gptkbp:bfsLayer
|
7
|